Compare TRUP & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRUP | DBVT |
|---|---|---|
| Founded | 2000 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 948.7M | 948.8M |
| IPO Year | 2014 | 2014 |
| Metric | TRUP | DBVT |
|---|---|---|
| Price | $23.69 | $16.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $45.80 | $32.04 |
| AVG Volume (30 Days) | ★ 352.2K | 257.3K |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 295.65 | 10.26 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $1,439,305,000.00 | $5,636,000.00 |
| Revenue This Year | $11.79 | $35.04 |
| Revenue Next Year | $8.83 | $2,360.78 |
| P/E Ratio | $222.18 | ★ N/A |
| Revenue Growth | 11.95 | ★ 35.77 |
| 52 Week Low | $21.16 | $8.50 |
| 52 Week High | $57.35 | $26.19 |
| Indicator | TRUP | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 54.83 | 38.59 |
| Support Level | $21.16 | $16.05 |
| Resistance Level | $29.24 | $17.42 |
| Average True Range (ATR) | 0.90 | 0.97 |
| MACD | 0.38 | 0.02 |
| Stochastic Oscillator | 75.90 | 20.50 |
Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue majorly from subscription fees related to the company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions. Geographically, the company operates in United States, which derives maximum revenue; and Canada and Others.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.